ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Self-Assembling Peptide-Adjuvant Conjugate (SaPAC) Platform for Precision Cancer Immunotherapy.
Yang-Fan Wu, Jing-Chu Hu, Ye-Fan Hu, Wen-Jun Li, Li Rong, Ren-Hao Li, Yuan Yao, Lehan Hu, Xiao-Lei Wang, Bao-Zhong Zhang and 6 more
Abstract read
In one paragraphArticle in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
16 authors.
Yang-Fan Wu *School of Biomedical Sciences and School of Biomedical Engineering, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, People's Republic of China.ORCID https://orcid.org/0000-0002-9932-208X Jing-Chu Hu *School of Biomedical Sciences and School of Biomedical Engineering, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, People's Republic of China.ORCID https://orcid.org/0000-0001-6144-7226 Wen-Jun LiSchool of Biomedical Sciences and School of Biomedical Engineering, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, People's Republic of China.
Li RongKey Laboratory of Quantitative Synthetic Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, People's Republic of China.
Ren-Hao LiSchool of Biomedical Sciences and School of Biomedical Engineering, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, People's Republic of China.ORCID https://orcid.org/0000-0002-6383-3240 Yuan YaoSchool of Biomedical Sciences and School of Biomedical Engineering, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, People's Republic of China.ORCID https://orcid.org/0009-0001-6101-3804 Lehan HuSchool of Biomedical Sciences and School of Biomedical Engineering, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, People's Republic of China.ORCID https://orcid.org/0009-0009-9574-0151 Xiao-Lei WangSchool of Biomedical Sciences and School of Biomedical Engineering, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, People's Republic of China.
Bao-Zhong ZhangKey Laboratory of Quantitative Synthetic Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, People's Republic of China.
Canhui SuSchool of Biomedical Sciences and School of Biomedical Engineering, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, People's Republic of China.
Thomas YauCentre of Cancer Medicine, School of Clinical Medicine, The University of Hong Kong, Pokfulam, Hong Kong, People's Republic of China.
Clive Yik-Sham ChungSchool of Biomedical Sciences and School of Biomedical Engineering, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, People's Republic of China.ORCID https://orcid.org/0000-0003-1382-719X Jian-Dong HuangSchool of Biomedical Sciences and School of Biomedical Engineering, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, People's Republic of China.ORCID https://orcid.org/0000-0001-7531-2816 Funding
A Special Research Fund from HKUNational Key Research and Development Program of China 2021YFA0910700National Natural Science Foundation of China (Major Program) 92369201Seed Fund for Translational and Applied Research 202111160012Shenzhen Key Laboratory for Cancer Metastasis and Personalized Therapy ZDSYS20210623091811035Shenzhen Medical Research Fund D2402020The Innovation and Technology Support Programme (Seed Project) ITS/365/23
6 · The paper itselfAbstract
Peptide cancer vaccines often suffer from poor lymphatic drainage, limited antigen-presenting cell uptake, and weak innate immune activation. To overcome these barriers, we engineered the Self-Assembling Peptide-Adjuvant Conjugate (SaPAC) platform, which covalently links neoantigen epitopes to the TLR7 agonist 1V209 through site-selective lysine conjugation. Synthesized by Fmoc solid-phase peptide synthesis, SaPAC conjugates self-assemble into cationic nanoparticles with hydrodynamic diameters of approximately 100-200 nm. Compared with unconjugated self-assembling peptide nanoparticles mixed with soluble adjuvant, SaPAC nanoparticles enhanced lymphatic drainage and antigen persistence in draining lymph nodes. Mechanistically, SaPAC activated the TLR7-MyD88 axis, promoted plasmacytoid dendritic cell and macrophage recruitment, drove APC maturation (CD80
Indexed as
lymph node deliverypeptide‐adjuvant conjugateprecision cancer immunotherapyself‐assembled peptide nanovaccineTLR7 conjugate neoantigen vaccine
Identifiers
PMID42827008
PMCPMC13633104
What Socratic holds
Textmetadata
Read underepoch 390